Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 Cells

Drug Metabolism and Disposition

Volumn 43, Issue 5, 2015, Pages 660-668

  Hu, Dong Gui ^a   Mackenzie, Peter I ^a   Lu, Lu ^a   Meech, Robyn ^a   McKinnon, Ross A ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FIRTECAN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 2B7; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IDARUBICIN; MITOMYCIN; PROTEIN P53; TOPOTECAN; GLUCURONOSYLTRANSFERASE; MESSENGER RNA; UGT2B7 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE SEQUENCE; GENE TARGETING; HEPG2 CELL LINE; IN VITRO STUDY; LIVER CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UGT2B7 GENE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940379692     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.062380     Document Type: Article

References (46)

1. Appella E and Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochemistry 268:2764-2772.
2. Argikar UA and Remmel RP (2009) Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 37:229-236.
3. Basseville A, Preisser L, de Carné Trécesson S, Boisdron-Celle M, Gamelin E, Coqueret O, and Morel A (2011) Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer 10:80.
4. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
5. Cosse JP, Rommelaere G, Ninane N, Arnould T, and Michiels C (2010) BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem Pharmacol 80:1160-1169.
6. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, and Pommier Y (2003) Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 63: 2782-2793.
7. Dellinger RW, Matundan HH, Ahmed AS, Duong PH, and Meyskens FL, Jr. (2012) Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS ONE 7: e47696.
8. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
9. Fritsche M, Haessler C, and Brandner G (1993) Induction of nuclear accumulation of the tumorsuppressor protein p53 by DNA-damaging agents. Oncogene 8:307-318.
10. Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, and Rotter V (2013) Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis 34:190-198.
11. Holohan C, Van Schaeybroeck S, Longley DB, and Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714-726.
12. Hu DG and Mackenzie PI (2009) Estrogen receptor a, Fos-related antigen-2, and c-Jun coordinately regulate human UDP glucuronosyltransferase 2B15 and 2B17 expression in response to 17b-estradiol in MCF-7 cells. Mol Pharmacol 76:425-439.
13. Hu DG, Meech R, Lu L, McKinnon RA, and Mackenzie PI (2014a) Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter. Drug Metab Dispos 42: 854-862.
14. Hu DG, Meech R, McKinnon RA, and Mackenzie PI (2014b) Transcriptional regulation of human UDP-glucuronosyltransferase genes. Drug Metab Rev 46:421-458.
15. Hu DG, Rogers A, and Mackenzie PI (2014c) Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway. Mol Pharmacol 85: 887-897.
16. Innocenti F, Iyer L, Ramírez J, Green MD, and Ratain MJ (2001) Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29:686-692.
17. Inoue T, Geyer RK, Yu ZK, and Maki CG (2001) Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett 490:196-201.
18. Italia C, Paglia L, Trabattoni A, Luchini S, Villas F, Beretta L, Marelli G, and Natale N (1983) Distribution of 49epi-doxorubicin in human tissues. Br J Cancer 47:545-547.
19. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
20. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, and Miners JO (2009) Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDPglucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos 37:1948-1955.
21. L'Espérance S, Bachvarova M, Tetu B, Mes-Masson AM, and Bachvarov D (2008) Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 9:99.
22. Liedtke C, Lambertz D, Schnepel N, and Trautwein C (2007) Molecular mechanism of Mitomycin C-dependent caspase-8 regulation: implications for apoptosis and synergism with interferon-Alpha signalling. Apoptosis 12:2259-2270.
23. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 22DDCT method. Methods 25:402-408.
24. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
25. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, and Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
26. Malmlof M, Paajarvi G, Hogberg J, and Stenius U (2008) Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci 102:232-240.
27. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, and Burroughs AK (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25.
28. Meijerman I, Beijnen JH, and Schellens JH (2008) Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 34:505-520.
29. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, and Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413.
30. O'Dwyer PJ and Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24: 4534-4538.
31. Pavelic J (2014) Editorial: combined cancer therapy. Curr Pharm Des 20:6511-6512.
32. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146.
33. Piret JP, Cosse JP, Ninane N, Raes M, and Michiels C (2006) Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res 312: 2908-2920.
34. Pluquet O and Hainaut P (2001) Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett 174:1-15.
35. Qin J, Lin Y, Norman RX, Ko HW, and Eggenschwiler JT (2011) Intraflagellar transport protein 122 antagonizes Sonic Hedgehog signaling and controls ciliary localization of pathway components. Proc Natl Acad Sci USA 108:1456-1461.
36. Resnick-Silverman L and Manfredi JJ (2006) Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J Cell Biochem 99:679-689.
37. Riley T, Sontag E, Chen P, and Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402-412.
38. Roudier E, Mistafa O, and Stenius U (2006) Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 5:2706-2715.
39. Saunders RA, Fujii K, Alabanza L, Ravatn R, Kita T, Kudoh K, Oka M, and Chin KV (2010) Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan. Biochem Pharmacol 80:362-369.
40. Schneider CA, Rasband WS, and Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675.
41. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, and Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
42. Takahata T, Ookawa K, Suto K, Tanaka M, Yano H, Nakashima O, Kojiro M, Tamura Y, Tateishi T, and Sakata Y, et al. (2008) Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Basic Clin Pharmacol Toxicol 102:399-407.
43. Tishler RB, Calderwood SK, Coleman CN, and Price BD (1993) Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53 (Suppl):2212-2216.
44. Tishler RB, Lamppu DM, Park S, and Price BD (1995) Microtubule-Active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 55: 6021-6025.
45. Wen Z, Tallman MN, Ali SY, and Smith PC (2007) UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos 35:371-380.
46. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab Dispos 32:1201-1208.